This company listing is no longer active
CEPS Stock Overview
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CTI BioPharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.23 |
| 52 Week High | US$8.44 |
| 52 Week Low | US$3.70 |
| Beta | 0.83 |
| 11 Month Change | -0.19% |
| 3 Month Change | 109.73% |
| 1 Year Change | 59.14% |
| 33 Year Change | 714.44% |
| 5 Year Change | 81.37% |
| Change since IPO | -69.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| CEPS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 1.2% | 1.0% |
| 1Y | 59.1% | -19.2% | 7.7% |
Return vs Industry: CEPS exceeded the German Biotechs industry which returned -8.9% over the past year.
Return vs Market: CEPS exceeded the German Market which returned 1.4% over the past year.
Price Volatility
| CEPS volatility | |
|---|---|
| CEPS Average Weekly Movement | 25.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CEPS's share price has been volatile over the past 3 months.
Volatility Over Time: CEPS's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 128 | Adam Craig | www.ctibiopharma.com |
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.
CTI BioPharma Corp. Fundamentals Summary
| CEPS fundamental statistics | |
|---|---|
| Market cap | €1.09b |
| Earnings (TTM) | -€63.16m |
| Revenue (TTM) | €69.12m |
15.8x
P/S Ratio-17.3x
P/E RatioIs CEPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEPS income statement (TTM) | |
|---|---|
| Revenue | US$75.77m |
| Cost of Revenue | US$4.46m |
| Gross Profit | US$71.31m |
| Other Expenses | US$140.55m |
| Earnings | -US$69.24m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 94.11% |
| Net Profit Margin | -91.38% |
| Debt/Equity Ratio | -459.4% |
How did CEPS perform over the long term?
See historical performance and comparison